Unseen Bio™ was founded in 2018 with a vision to increase awareness of the importance of gut health as a means of preventing disease. Our mission is to strengthen the microbiome in order to improve the biodiversity crisis in the gut. Based on a thorough analysis of the microbiome, we provide personal dietary recommendations aimed at increasing biodiversity and improving gut health for the individual. Based on the latest knowledge in the microbiome area and with a focus on preventive healthcare, we are constantly developing our digital platform for intestinal health Digital Gut™.

At Surveypal, we’re reimagining how businesses understand and improve customer experiences through meaningful feedback. Our solutions make it easy for companies to gather, analyze, and act on customer feedback, transforming data into insights that help businesses grow. As we continue to evolve, we're looking for talented pals to join our team. You'll work on cutting-edge solutions that empower businesses to make smarter decisions based on real-time data. We’re a hybrid team passionate about solving problems, learning together, and pushing the boundaries of what’s possible in customer experience management. If you're eager to build software that makes a real difference and enjoy collaborating in an open, supportive environment, Surveypal could be the perfect fit for you. Join us on our mission to make feedback more impactful and be part of shaping the future of customer experience!

Niuton is a deep tech platform that works on autonomous and decentralized solutions based on Newtonian principles and our end customers are hedge funds. Currently, we have a team of five people, the tech dev and research stretches three years back and we have been with one year live with clients. Now we are looking for a senior python specialist to automate the data flow in and out of our core machinery. The data feed into Niutons machinery is from Twelvedata and the output is clients around the world. For the right candidate, we can consider offering 0.5% of shares equity (valuation right now 7.5 million USD), you will be assisted by our other senior python specialist that handles the core machinery itself. The expected duration of this assignment is three to four months ONLY. Start date 1. January 2022. Resources have to be available 100% of the time during the assignment, most preferably in Oslo. The MVP is ready, Niuton is now exactly what we want, and the success criterion is achieving 99% uptime on a day-to-day basis.

OKTO is a gamification of outdoor cycling. OKTO gives you the fun of friendly competition, you compete with riders on your own level - both locally and all over the world. By completing quests, journeys, and achievements you gain OKTO points, fun rewards, titles, and more to help you reach the next level.

CatalystOne Solutions is a rapidly growing SaaS company with over 200 passionate employees who all work towards a common goal: enabling businesses to thrive. We don't consider ourselves merely a software supplier, but as a partner who works closely with our customers to ensure they gain the maximum value from their HR solution. That's why we provide consistent support and deliver results beyond expectations. Our purpose is to enable businesses to thrive.

Humans for Humans is a non-governmental organization that provides free mental health support for human trafficking survivors, those indirectly affected by human trafficking, and the professionals who work with them. Moreover, we aim to promote the anti-trafficking movement and contribute to the awareness and eradication of modern slavery.

We are simplifying personal health control, by making clinically proven testing readily available to the public. Tigeni is a healthcare and technology company that makes blood screening convenient, safe and monitorable in a simple, personal and secure health dashboard. Tigeni offers at-home-finger-prick-test, monitoring and test results with professional lifestyle guidance, accessible on PC and mobile. Through innovation, information and motivation, we are empowering our customers to take control of their health and live better lives.

Det er stor konkurranse om de beste hodene i Norge, og det strekker desverre ikke til for alle de fantastiske idèene og bedriftene vi har.Outsourcing er sjeldent en god løsning da det bringer høy kompleksitet, lav utviklingshastighet og store sjanser for kommunikasjonsproblemer. Behovet for A-lags-spillere er høyt.Homesourcing finner fantastiske personer i Europa og integrerer de i norske utviklingsteam. Vi mener det finnes mer enn nok av utviklere i verden, men for få utviklere som også har lederevner. Vi coacher og bygger utviklere til ledere for å sørge for de blir like effektive som oss nordmenn og kan ta et større ansvar. Ikke minst kunne tenke selv og ta gode avgjørelser for teamene de er i.

At Aivero we strive to bring AI to industrial robotics. We are a young and dynamic startup with offices in Norway and Denmark Aivero is a Scandinavian startup founded in 2017 with a mission to democratize automation by simplifying robotic control to the point where anyone can deploy and operate them. No more code, programming, or complex path planning—vision-guided robotics automates this too.

7Mountains was founded in 2018 by a team of broadcast engineers and software developers in Norway. 7Mountains is part of Fonn Group and is headquartered in Media City Bergen, Norway. The majority owner is Rieber & Søn, a family-owned Norwegian investment company with an industrial legacy dating back to 1839. 7Mountains has founded Dina - a newsroom and storytelling solution changing how journalists work for story planning, creation and collaboration. Want to know more? Get in touch!

Sensar Marine is set out to revolutionize the boating industry. Using the latest sensor and wireless technology we will improve safety at sea, protect the boat when not in use and give boat owners and their families peace of mind wherever they are. Sensar Marine makes products designed to improve the relationship between a boat and its owner. Our flagship product is a boat monitoring system designed specifically for use in boats, which could run 24/7, 365 days a year without draining boat batteries. Our service has introduced a way for boaters to monitor their boats from their mobile phones, and be notified when their boat needs attention. To date, SmartBoat One has been installed in thousands of boats of all types, in harbors around the world.

Amina Charging is a technology startup on a mission to give our planet a greener future by scaling the transition to electric vehicles (EV). We create environmental sustainability solutions grounded in sound business and global scalability. We work and play with curiosity, creativity and ambition. At Amina, we never compromise on sustainability, scale and sound business. We work with passion and insight, and prize impact and progress over process. We empower your creative autonomy but you will never struggle alone. We work as a team in an open culture that rewards sharing ideas and supporting each other.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

Hvorfor velge oss? Tradisjonell varehandel står ovenfor store utfordringer i konkurranse med veksten i netthandel. Spesielt presserende er utfordringer i forhold til kjøpsopplevelse, effektivitet og lønnsomhet. ​ Vårt fokus i Qtime er å hjelpe varehandelen til å løse nettopp disse utfordringene. Gi kundene dine den beste handleopplevelsen, med fremtidens kundestrømsverktøy.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.